# US 2006/0154860 A1 · Manipulating stem-progenitor cell trafficking to injured tissue and/or tumors by altering HIF-1 and/or SDF-1 activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154860 A1
- Document ID: US20060154860A1
- Status: Published application
- Kind: A1
- Application number: 11/187,585
- Filed: 2005-07-22
- Published: 2006-07-13
- Earliest claimed: 2004-07-22
- Inventors: Daniel Ceradini; Geoffrey Gurtner
- Web page: https://patentgrep.com/patent/US20060154860A1

## CPC

- C07K 14/4702: {Regulators; Modulating activity}
- A01K 2267/03: Animal model, e.g. for test or diseases
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a method for modulating recruitment of stem cells or progenitor cells to a selected tissue site. Methods for treating damaged tissue and for treating cancerous tumor tissue are also disclosed. These methods involve regulating HIF-1 and/or SDF-1 activity in the tissue.

## Claims

### Claim 1

A method of treating damaged tissue, said method comprising:
increasing activity of hypoxia-inducible factor-1 and/or activity of stromal cell-derived factor-1 in damaged tissue to a level above that caused by damage alone to the tissue, under conditions effective to treat the damaged tissue.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the tissue is in vitro.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the tissue is in vivo.

### Claim 4 (depends on 4)

The method according to claim 4, wherein the tissue is in a human patient.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the damaged tissue is selected from the group comprising ischemic tissue, tissue located at a wound site, and combinations thereof.

### Claim 6 (depends on 1)

The method according to claim 1, wherein activity of hypoxia-inducible factor-1 is increased.

### Claim 7 (depends on 1)

The method according to claim 1, wherein activity of stromal cell-derived factor-1 is increased.

### Claim 8 (depends on 7)

The method according to claim 7, wherein activity of stromal cell-derived factor-1 is increased by increasing expression of stromal cell-derived factor-1.

### Claim 9 (depends on 8)

The method according to claim 8, wherein expression of stromal cell-derived factor-1 is increased by increasing the activity hypoxia-inducible factor-1.

### Claim 10

A method of modulating recruitment of stem cells and/or progenitor cells to a selected tissue site, said method comprising:
controlling activity of hypoxia-inducible factor-1 and/or activity of stromal cell-derived factor-1 at the selected tissue site to a level different than activity otherwise present at the selected tissue site, under conditions effective to modulate recruitment of stem cells and/or progenitor cells to the selected tissue site.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the tissue is in vitro.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the tissue is in vivo.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the tissue is in a human patient.

### Claim 14 (depends on 10)

The method according to claim 10, wherein activity of hypoxia-inducible factor-1 is increased, whereby recruitment of stem cells and/or progenitor cells to the selected tissue site is increased.

### Claim 15 (depends on 10)

The method according to claim 10, wherein activity of hypoxia-inducible factor-1 is decreased, whereby recruitment of stem cells and/or progenitor cells to the selected tissue site is diminished.

### Claim 16 (depends on 10)

The method according to claim 10, wherein activity of stromal cell-derived factor-1 is increased, whereby recruitment of stem cells and/or progenitor cells to the selected tissue site is increased.

### Claim 17 (depends on 16)

The method according to claim 16, wherein activity of stromal cell-derived factor-1 is increased by increasing expression of stromal cell-derived factor-1.

### Claim 18 (depends on 17)

The method according to claim 17, wherein expression of stromal cell-derived factor-1 is increased by increasing activity of hypoxia-inducible factor-1.

### Claim 19 (depends on 10)

The method according to claim 10, wherein activity of stromal cell-derived factor-1 is decreased, whereby recruitment of stem cells and/or progenitor cells to the selected tissue site is diminished.

### Claim 20 (depends on 19)

The method according to claim 19, wherein activity of stromal cell-derived factor-1 level is decreased by decreasing expression of stromal cell-derived factor-1.

### Claim 21 (depends on 20)

The method according to claim 20, wherein expression of stromal cell-derived factor-1 is decreased by decreasing activity of hypoxia-inducible factor-1.

### Claim 22 (depends on 10)

The method according to claim 10, wherein the selected tissue site is selected from the group comprising a site where there is ischemia, a site where there is damaged tissue, a wound site, a tumor site, a site where there is tissue susceptible to damage, or combinations thereof.

### Claim 23 (depends on 10)

The method according to claim 10, wherein CXCR4+ cells are recruited.

### Claim 24

A method of treating cancer in a subject, said method comprising:
limiting activity of hypoxia-inducible factor-1 and/or activity of stromal cell-derived factor-1 in cancerous tumor tissue in the subject under conditions effective to treat the subject's cancer.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the subject is a human.

### Claim 26 (depends on 24)

The method according to claim 24, wherein the cancer is selected from the group consisting of breast cancer, colon cancer, central nervous system cancer, leukemia, melanoma, lung cancer, ovarian cancer, prostate cancer, and renal cancer.

### Claim 27 (depends on 24)

The method according to claim 24, wherein activity of hypoxia-inducible factor-1 is limited.

### Claim 28 (depends on 24)

The method according to claim 24, wherein activity of stromal cell-derived factor-1 is limited.

### Claim 29 (depends on 28)

The method according to claim 28, wherein activity of stromal cell-derived factor-1 is limited by limiting expression of stromal cell-derived factor-1.

### Claim 30 (depends on 29)

The method according to claim 29, wherein expression of stromal cell-derived factor-1 is limited by limiting activity of hypoxia-inducible factor-1.
